Comparative Performance Analysis of Idylla and Archer in the Detection of Gene Fusions in Spitzoid Melanocytic Tumors

• Published in: Modern pathology Vol. 37; no. 8; p. 100538
• Main Authors: Ebbelaar, Chiel F., van Dijk, Marijke, Breimer, Gerben E., Meijers, Ruud W.J., Klein, Laura B.C., Petronilia, Maryleen M., de Leng, Wendy W.J., Blokx, Willeke A.M., Jansen, Anne M.L.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.08.2024
• Subjects: Archer; gene fusions; Idylla; molecular diagnostics; spitzoid; Idylla; molecular diagnostics; spitzoid; Archer; gene fusions
• ISSN: 0893-3952; 1530-0285; 1530-0285
• DOI: 10.1016/j.modpat.2024.100538

Melanocytic neoplasms with spitzoid histomorphology are often difficult to classify without identifying genetic drivers such as kinase fusions. Traditional diagnostic methods, such as immunohistochemistry, can yield inconclusive results, and advanced techniques such as the Archer fusion assay are often inaccessible and costly. The Idylla GeneFusion Assay might offer a rapid and cost-effective alternative. This study compared Idylla and Archer in identifying ALK, pan-NTRK, RET, and ROS1 gene fusions. Of the 147 samples where next-generation sequencing did not detect genetic drivers, 89 (60.5%) meeting the tissue requirements were further analyzed using Idylla (Cohort A). Idylla demonstrated a sensitivity of 75% and a specificity of 100% in detecting these fusions. Additionally, among 27 randomly selected cases (Cohort B) that failed to meet the inclusion criteria, Idylla maintained the same levels of sensitivity and specificity. Our findings also show that Idylla can be effectively conducted with isolated RNA, broadening its applicability beyond tissue samples. Although the Idylla assay may not replace more comprehensive molecular assays such as Archer, it could serve as a valuable initial screening tool in diagnosing spitzoid melanocytic tumors.